CREATE Medicines ("CREATE") broadens clinical programs and capabilities to expand therapeutic potential and improve patient outcomes Therapies tolerably program immune cells inside the human body, ...
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, and public reviews. The manuscript by Xu et al. reported base-resolution mapping of ...
A few years after it was founded with the aim of taking RNA therapies to the next level, Arnatar Therapeutics Inc. emerged from stealth, disclosing a $52 million series A round raised in 2024 as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback